Repeating late-phase pseudo-progression in a patient with non-small cell lung cancer treated with long-term nivolumab monotherapy; a case report

Repeating late-phase pseudo-progression in a patient with non-small cell lung cancer treated with long-term nivolumab monotherapy; a case report

BackgroundImmune check point inhibitors (ICIs) are standard treatment for patients with non-small cell lung cancer (NSCLC). Nearly a decade has passed since nivolumab was approved by the FDA for NSCLC patients. However, long-term outcomes and clinical features remain unclear for individual cases. Ps...

Full description

Bibliographic Details
Main Authors: Rikako Ebisuda, Naoki Furuya, Takeo Inoue, Shotaro Kaneko, Yu Numata, Yusuke Shinozaki, Masamichi Mineshita
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-07-01
Series:Frontiers in Oncology
Subjects:
pseudo-progression
nivolumab
non-small cell lung cancer
lymph node enlargement
long-term response
long-term survival
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2024.1353698/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2024.1353698/full

Similar Items